Sphingosine-1-phosphate acts as a key molecule in the direct mediation of renal fibrosis

Physiological Reports

Volumn 1, Issue 7, 2013, Pages

  Shiohira, Shunji ^a   Yoshida, Takumi ^a,b   Sugiura, Hidekazu ^a   Nishida, Miki ^a   Nitta, Kosaku ^a   Tsuchiya, Ken ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^b Yoshida Medical Clinic   (Japan)

Author keywords

DMS; FTY720; Renal fibrosis; Sphingosine 1 phosphate; UUO

Indexed keywords

ANTIFIBROTIC AGENT; COLLAGEN TYPE 1; COLLAGEN TYPE 4; DIMETHYL SULFOXIDE; FINGOLIMOD; INTERSTITIAL COLLAGENASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; SPHINGOSINE 1 PHOSPHATE; UVOMORULIN;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CELL CULTURE; CELL MIGRATION; CELL MIGRATION ASSAY; CONTROLLED STUDY; FIBROBLAST; GENE EXPRESSION; GENE EXPRESSION REGULATION; HISTOLOGY; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; KIDNEY FIBROSIS; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; RNA ISOLATION; URETER OBSTRUCTION; WESTERN BLOTTING;

EID: 85008937021     PISSN: None     EISSN: 2051817X     Source Type: Journal    
DOI: 10.1002/phy2.172     Document Type: Article

References (35)

1. Arana, L., P. Gangoiti, A. Ouro, M. Trueba, and A. Gómez Munoz. 2010. Ceramide and ceramide 1-phosphate in health and disease. Lipids Health Dis. 9:15.
2. Awad, A., H. Ye, L. Huang, L. Li, F. Foss, T. Macdonald, et al. 2006. Selective sphingosine 1-phosphate 1 receptor activation reduces ischemia-reperfusion injury in mouse kidney. Am. J. Physiol. Renal Physiol. 290:F1516-F1524.
3. Barnes, J., and W. Glass. 2011. Renal interstitial fibrosis: a critical evaluation of the origin of myofibroblasts. Contrib. Nephrol. 169:73-93.
4. Billich, A., and T. Baumruker. 2008. Sphingolipid metabolizing enzymes as novel therapeutic targets. Subcell. Biochem. 49:487-522.
5. Brunati, A., E. Tibaldi, A. Carraro, E. Gringeri, F. D’Amico, A. Toninello, et al. 2008. Cross-talk between PDGF and S1P signalling elucidates the inhibitory effect and potential antifibrotic action of the immunomodulator FTY720 in activated HSC-cultures. Biochim. Biophys. Acta 1783: 347-359.
6. Cencetti, F., C. Bernacchioni, P. Nincheri, C. Donati, and P. Bruni. 2010. Transforming growth factor-beta1 induces transdifferentiation of myoblasts into myofibroblasts via up-regulation of sphingosine kinase-1/S1P3 axis. Mol. Biol. Cell 21:1111-1124.
7. Chiba, K. 2005. FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptors. Pharmacol. Ther. 108:308-319.
8. Depierreux, M., B. Van Damme, K. Vanden Houte, and J. L. Vanherweghem. 1994. Pathologic aspects of a newly described nephropathy related to the prolonged use of Chinese herbs. Am. J. Kidney Dis. 24:172-180.
9. Gasperini, C., S. Ruggieri, C. Mancinelli, and C. Pozzilli. 2013. Advances in the treatment of relapsing-remitting multiple sclerosis-critical appraisal of fingolimod. Ther. Clin. Risk Manag. 9:73-85.
10. Hla, T., P. Grundy, F. Ferrer, and S. Thangada. 2012. Connective tissue growth factor (CTGF) and sphingosine-1-phosphate (S1P) receptor 1 and 2 levels are altered in Wilm’s tumor. J. Urol. 187:E62-E62.
11. Hodgkins, K., and H. W. Schnaper. 2012. Tubulointerstitial injury and the progression of chronic kidney disease. Pediatr. Nephrol. 27:901-909.
12. Huang, K., W. Liu, T. Lan, X. Xie, J. Peng, J. Huang, et al. 2012. Berberine reduces fibronectin expression by suppressing the S1P-S1P2 receptor pathway in experimental diabetic nephropathy models. PLoS ONE 7:e43874-e43874.
13. Huwiler, A., and J. Pfeilschifter. 2008. New players on the center stage: sphingosine 1-phosphate and its receptors as drug targets. Biochem. Pharmacol. 75:1893-1900.
14. Ikeda, H., N. Watanabe, I. Ishii, T. Shimosawa, Y. Kume, T. Tomiya, et al. 2009. Sphingosine 1-phosphate regulates regeneration and fibrosis after liver injury via sphingosine 1-phosphate receptor 2. J. Lipid Res. 50:556-564.
15. Kawashima, T., R. Yamazaki, Y. Matsuzawa, E. Yamaura, M. Takabatake, S. Otake, et al. 2012. Contrary effects of sphingosine-1-phosphate on expression of alpha-smooth muscle actin in transforming growth factor beta 1-stimulated lung fibroblasts. Eur. J. Pharmacol. 696:120-129.
16. Keller, C., P. R. Gil, M. Tolle, M. van der Giet, J. Chun, H. Radeke, et al. 2007. Immunomodulator FTY720 induces myofibroblast differentiation via the lysophospholipid receptor S1P3 and Smad3 signaling. Am. J. Pathol. 170: 281-292.
17. Kono, Y., T. Nishiuma, Y. Nishimura, Y. Kotani, T. Okada, S. I. Nakamura, et al. 2007. Sphingosine kinase 1 regulates differentiation of human and mouse lung fibroblasts mediated by TGF-beta1. Am. J. Respir. Cell Mol. Biol. 37:395-404.
18. Lee, S., and R. Kalluri. 2010. Mechanistic connection between inflammation and fibrosis. Kidney Int. Suppl. 119: S22-S26.
19. Li, M. H., T. Sanchez, A. Pappalardo, K. Lynch, T. Hla, and F. Ferrer. 2008. Induction of antiproliferative connective tissue growth factor expression in Wilms’ tumor cells by sphingosine-1-phosphate receptor 2. Mol. Cancer Res. 6:1649-1656.
20. Liu, J., C. Zhang, W. Tao, and M. Liu. 2013. Systematic review and meta-analysis of the efficacy of sphingosine-1-phosphate (S1P) receptor agonist FTY720 (fingolimod) in animal models of stroke. Int. J. Neurosci. 123:163-169.
21. Man, K., K. Ng, T. Lee, C. Lo, C. Sun, X. Li, et al. 2005. FTY720 attenuates hepatic ischemia-reperfusion injury in normal and cirrhotic livers. Am. J. Transplant. 5:40-49.
22. McDonald, R., S. Pyne, N. Pyne, A. Grant, C. Wainwright, and R. Wadsworth. 2010. The sphingosine kinase inhibitor N,N-dimethylsphingosine inhibits neointimal hyperplasia. Br. J. Pharmacol. 159:543-553.
23. Mitobe, M., T. Yoshida, H. Sugiura, S. Shiohira, K. Shimada, K. Nitta, et al. 2010. Clinical effects of calcium channel blockers and renin-angiotensin-aldosterone system inhibitors on changes in the estimated glomerular filtration rate in patients with polycystic kidney disease. Clin. Exp. Nephrol. 14:573-577.
24. Okusa, M., and K. Lynch. 2007. Targeting sphingosine 1 phosphate receptor type 1 receptors in acute kidney injury. Drug Discov. Today Dis. Mech. 4:55-59.
25. Peters, H., S. Martini, Y. Wang, F. Shimizu, H. Kawachi, S. Krämer, et al. 2004. “Selective lymphocyte inhibition by FTY720 slows the progressive course of chronic anti-thy 1 glomerulosclerosis. Kidney Int. 66:1434-1443.
26. Roberts, E., M. Guerrero, M. Urbano, and H. Rosen. 2013. Sphingosine 1-phosphate receptor agonists: a patent review (2010-2012). Expert Opin. Ther. Pat. 23:817-841.
27. Salata, D., M. Budkowska, and B. Dołegowska. 2012. Sphingosine-1-phosphate-molecular maestro. Postȩpy Biochem. 58:281-291.
28. Schwalm, S., J. Pfeilschifter, and A. Huwiler. 2013. Sphingosine-1-phosphate: a Janus-faced mediater of fibrotic diseases. Biochim. Biophys. Acta 1831:239-250.
29. Shuyu, R., B. Andrea, M. Kristin, X. Cuiyan, E. Wolfgang, D. Anke, et al. 2009. Transforming growth factor-β2 upregulates sphingosine kinase-1 activity, which in turn attenuates the fibrotic response to TGF-.β2 by impending CTGF expression. Kidney Int. 76:857-867.
30. Sugiura, H., T. Yoshida, S. Shiohira, J. Kohei, M. Mitobe, H. Kurosu, et al. 2012. Reduced Klotho expression level in kidney aggravates renal interstitial fibrosis. Am. J. Physiol. Renal Physiol. 302:F1252-F1264.
31. Swaney, J., K. Moreno, A. Gentile, R. Sabbadini, and G. Stoller. 2008. Sphingosine-1-phosphate (S1P) is a novel fibrotic mediator in the eye. Exp. Eye Res. 87:367-375.
32. Takuwa, N., S. I. Ohkura, S. I. Takashima, K. Ohtani, Y. Okamoto, T. Tanaka, et al. 2010. S1P3-mediated cardiac fibrosis in sphingosine kinase 1 transgenic mice involves reactive oxygen species. Cardiovas. Res. 85:484-493.
33. Wang, Q., W. Usinger, B. Nichols, J. Gray, L. Xu, T. Seeley, et al. 2011. Cooperative interaction of CTGF and TGF-β in animal models of fibrotic disease. Fibrogenesis Tissue Repair 4:4.
34. Watterson, K., D. Lanning, R. Diegelmann, and S. Spiegel. 2007. Regulation of fibroblast functions by lysophospholipid mediators: potential roles in wound healing. Wound Repair Regen. 15:607-616.
35. Yoshida, T., H. Sugiura, M. Mitobe, K. Tsuchiya, and S. Shirota. 2008. ATF3 protects against renal ischemia-reperfusion injury. J. Am. Soc. Nephrol. 19:217-224.